News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...
Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback